Trial · NCT05372354
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with adverse events (AEs) | From first participant first visit until 28 days after the last participant discontinues study treatment, up to approximately 4 years | |
| Primary | Number of participants with Serious AEs | Up to approximately 4 years | |
| Primary | Number of participants with AEs meeting protocol-defined DLT criteria | Up to approximately 4 years | |
| Primary | Number of participants with AEs leading to discontinuation | Up to approximately 4 years | |
| Primary | Number of deaths | Up to approximately 4 years | |
| Primary | Establish recommended Phase 2 dose (RP2D) | Up to approximately 2 years | |
| Primary | Establish dosing schedule of each combination for Part 2 Dose Expansion | Up to approximately 2 years | |
| Secondary | Overall response rate (ORR) | Up to approximately 4 years | |
| Secondary | Very good partial response rate (VGPRR) | Up to approximately 4 years | |
| Secondary | Complete response rate (CRR) | Up to approximately 4 years | |
| Secondary | Time-to-response (TTR) | Up to approximately 4 years | |
| Secondary | Duration of response (DOR) | Up to approximately 4 years | |
| Secondary | Progression-free survival (PFS) | Up to approximately 4 years | |
| Secondary | Maximum observed plasma concentration (Cmax) | Up to approximately 28 days | |
| Secondary | Time to maximum plasma concentration (Tmax) | Up to approximately 28 days | |
| Secondary | Area under the concentration-time curve (AUC) | Up to approximately 28 days | |
| Secondary | Terminal Half-Life (T-Half) | Up to approximately 28 days | |
| Secondary | Apparent total body clearance (CLT/F) | Up to approximately 28 days | |
| Secondary | Apparent volume of distribution (Vz/F) | Up to approximately 28 days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05372354/registered